Chai Peptides reading list

MOTS-c experiments and observations

The CK2 paper concerns tissue-specific activity and muscle effects in mice and laboratory assays. The exercise paper tests physical performance in mice; the nuclear-translocation paper follows a peptide inside human and mouse cells. The 2023 review brings that biology together.

The hemodialysis cohort asks a different question: whether natural blood levels help predict outcomes. It administered no MOTS-c. My concern with that distinction returns whenever a human association is offered as treatment evidence.

Tesamorelin hormone experiments and fat trials

The healthy-men experiment examines hormone release and insulin sensitivity. The six-month HIV trial measures visceral and liver fat, while the 52-week programme follows the abdominal-fat benefit and its loss after stopping. The 2026 meta-analysis pools five randomized trials in HIV-associated lipodystrophy.

The LiverTox chapter is a drug-safety reference, with the approved indication and an assessment of liver injury. It is not another treatment trial.

Tirzepatide: development, comparisons and harm

The early development report spans laboratory work, mice and early human testing. The receptor-signalling study investigates how the molecule engages its targets.

The direct comparisons are SURPASS-2 in type 2 diabetes and SURMOUNT-5 in obesity. The SURMOUNT-1 obesity trial uses placebo as its comparator. The pancreatitis and biliary-disease review pools safety findings, while StatPearls is a clinical reference chapter whose earlier description of weight use predates the separate weight-management approval.

These reports support the individual findings discussed here. I have no combination-trial result to add to them.